You are here

Article info

Article menu
Immune cell therapies and immune cell engineering
Original research
The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL

Authors

  • Kai Rejeski Department of Medicine III, Hematology and Oncology, University Hospital, LMU Munich, Munich, GermanyLaboratory for Translational Cancer Immunology, LMU Gene Center, Munich, GermanyGerman Cancer Consortium (DKTK) Munich Site, and German Cancer Research Center, Heidelberg, Germany PubMed articlesGoogle scholar articles
  • Ariel Perez Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, USABlood & Marrow Transplant Program, Miami Cancer Institute, Miami, Florida, USA PubMed articlesGoogle scholar articles
  • Gloria Iacoboni Department of Hematology, Vall d’Hebron Institute of Oncology (VHIO), University Hospital Vall d’Hebron, Universitat Autònoma of Barcelona (UAB), Department of Medicin, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Olaf Penack Department of Hematology, Oncology and Tumorimmunology, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, GermanyGerman Cancer Consortium (DKTK) Berlin Site, and German Cancer Research Center, Heidelberg, Germany PubMed articlesGoogle scholar articles
  • Veit Bücklein Department of Medicine III, Hematology and Oncology, University Hospital, LMU Munich, Munich, GermanyLaboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany PubMed articlesGoogle scholar articles
  • Liv Jentzsch Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Dimitrios Mougiakakos Department of Internal Medicine 5, Hematology and Oncology, University of Erlangen-Nuremberg, Erlangen, Germany PubMed articlesGoogle scholar articles
  • Grace Johnson USF Morsani College of Medicine, Tampa, Florida, USA PubMed articlesGoogle scholar articles
  • Brian Arciola USF Morsani College of Medicine, Tampa, Florida, USA PubMed articlesGoogle scholar articles
  • Cecilia Carpio Department of Hematology, Vall d’Hebron Institute of Oncology (VHIO), University Hospital Vall d’Hebron, Universitat Autònoma of Barcelona (UAB), Department of Medicin, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Viktoria Blumenberg Department of Medicine III, Hematology and Oncology, University Hospital, LMU Munich, Munich, GermanyLaboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany PubMed articlesGoogle scholar articles
  • Eva Hoster Institute for Medical Information Processing, Biometry and Epidemiology (IBE), LMU Munich, Munich, Germany PubMed articlesGoogle scholar articles
  • Lars Bullinger Department of Hematology, Oncology and Tumorimmunology, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, GermanyGerman Cancer Consortium (DKTK) Berlin Site, and German Cancer Research Center, Heidelberg, Germany PubMed articlesGoogle scholar articles
  • Frederick L Locke Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, USA PubMed articlesGoogle scholar articles
  • Michael von Bergwelt-Baildon Department of Medicine III, Hematology and Oncology, University Hospital, LMU Munich, Munich, GermanyGerman Cancer Consortium (DKTK) Munich Site, and German Cancer Research Center, Heidelberg, Germany PubMed articlesGoogle scholar articles
  • Andreas Mackensen Department of Internal Medicine 5, Hematology and Oncology, University of Erlangen-Nuremberg, Erlangen, Germany PubMed articlesGoogle scholar articles
  • Wolfgang Bethge Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Pere Barba Department of Hematology, Vall d’Hebron Institute of Oncology (VHIO), University Hospital Vall d’Hebron, Universitat Autònoma of Barcelona (UAB), Department of Medicin, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Michael D Jain Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, USA PubMed articlesGoogle scholar articles
  • Marion Subklewe Department of Medicine III, Hematology and Oncology, University Hospital, LMU Munich, Munich, GermanyLaboratory for Translational Cancer Immunology, LMU Gene Center, Munich, GermanyGerman Cancer Consortium (DKTK) Munich Site, and German Cancer Research Center, Heidelberg, Germany PubMed articlesGoogle scholar articles

Citation

Rejeski K, Perez A, Iacoboni G, et al
The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL
Journal for ImmunoTherapy of Cancer 2022;10:e004475. doi: 10.1136/jitc-2021-004475
Online issue publication 
May 17, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.